Back to Search
TRAVIS WHITESIDE, PHARM.D.
PHARM.D.
Pharmacist
NPI: 1518235753Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
16737(AL)
Research & Publications (20)
Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors.
PMID 19526239·Cancer Immunol Immunother·2010
8-other
CIITA versus IFN-gamma induced MHC class II expression in head and neck cancer cells.
PMID 19104823·Arch Dermatol Res·2009
8-other
CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.
PMID 19184003·Cancer Immunol Immunother·2009
8-other
Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.
PMID 19318560·Cancer Res·2009
8-other
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.
PMID 19543393·PLoS One·2009
8-other
Spontaneous apoptosis of tumor-specific tetramer+ CD8+ T lymphocytes in the peripheral circulation of patients with head and neck cancer.
PMID 19296526·Head Neck·2009
4-observational
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
PMID 19228745·Clin Cancer Res·2009
3-trial
A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration.
PMID 19208382·Int J Cancer·2009
8-other
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.
PMID 19640287·J Transl Med·2009
3-trial
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
PMID 19180118·Cell Death Differ·2009
8-other
Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.
PMID 19170985·Transfusion·2009
6-review
Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis.
PMID 19155494·J Immunol·2009
4-observational
The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
PMID 19307994·J Immunother·2009
3-trial
Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression.
PMID 19450601·J Immunol Methods·2009
8-other
Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression.
PMID 19073006·Head Neck·2009
8-other
Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection.
PMID 19038780·Clin Vaccine Immunol·2009
8-other
Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.
PMID 18986219·Hum Gene Ther·2009
3-trial
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
PMID 18931824·Invest New Drugs·2009
3-trial
Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia.
PMID 19417016·Clin Cancer Res·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3551 ROGER BROOKE DR, DEPT OF PHARMACY, BROOKE ARMY MEDICAL CENTER (BAMC)
FT. SAM HOUSTON, TX 78234 - Phone
- (210) 916-7633
Quick Facts
- NPI
- 1518235753
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile